Cancer Chemotherapy Market Size, Share & Global Insights (2022–2031)
The global cancer chemotherapy market is poised for substantial growth — projected to reach US$ 84,044.04 million by 2031 from US$ 39,509.70 million in 2024, registering an impressive CAGR of 11.5% from 2025 to 2031.
๐ Executive Summary & Market
Dynamics:
Growth is
fueled by the rising global incidence of cancer, an aging population,
and expanding access to oncology care, particularly in emerging markets.
Chemotherapy — encompassing alkylating agents, antimetabolites, anti-tumor
antibiotics, topoisomerase inhibitors, and mitotic inhibitors
— remains a cornerstone of cancer treatment.
According
to NIH estimates, around 650,000 cancer patients in the US receive
chemotherapy each year. The therapeutic goal: shrink tumors to facilitate
surgical removal and improve patient outcomes.
๐ฅ Grab Sample PDF to Learn More:
๐ Download PDF Sample
๐ฌ Market Segmentation:
- By Therapy Type: Alkylating agents dominate,
driven by their broad applicability and affordability.
- By Indication: Lung cancer led market
share in 2024.
- By Distribution Channel: Hospital pharmacies held
the largest share.
๐ Key Growth Driver:
Increased
access to oncology care in emerging markets such as Asia-Pacific, Latin America, and parts of
Africa is a major driver. Investments in healthcare infrastructure, universal
health coverage, and inclusion of chemotherapy drugs in essential medicine
lists are improving treatment access significantly.
๐งช Leading Companies:
- Astellas Pharma Inc
- Eli Lilly and Co
- Novartis AG
- Merck KGaA
- Johnson & Johnson
- AstraZeneca
- Pfizer Inc
- Bristol Myers Squibb
- F. Hoffmann-La Roche Ltd
- AbbVie
๐ About Us:
Business Market Insights delivers intelligent, data-driven insights
across healthcare, automotive, electronics, aerospace, and more—empowering
stakeholders to make informed strategic decisions.
Comments
Post a Comment